Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Iovance BiotherapeuticsIOVA +5.77%34 3-Year EPS without NRI Growth Rate is 24.40% as of Jun. 2026. GuruFocus rates IOVA with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,160 Biotechnology companies, Iovance Biotherapeutics ranks better than 60.69% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 24.40% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 12.60% per year.
During the past 10 years, the average EPS without NRI Growth Rate was -8.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Iovance Biotherapeutics was 76.30% per year. The lowest was -229.90% per year. And the median was -15.65% per year.
Iovance Biotherapeutics (NAS:IOVA) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Iovance Biotherapeutics 3-Year EPS without NRI Growth Rate Related Terms
IOVA vs ABCL, RCUS, VKTX: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Iovance Biotherapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iovance Biotherapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Iovance Biotherapeutics's 3-Year EPS without NRI Growth Rate falls into.
Iovance Biotherapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 24.40% mean?
Iovance Biotherapeutics (IOVA) has a 3-Year EPS without NRI Growth Rate of 24.40% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Iovance Biotherapeutics and its competitors. According to the industry distribution chart, Iovance Biotherapeutics ranks #456 out of 1160 companies in the Biotechnology industry, placing it in the top 39.3%.
Is Iovance Biotherapeutics' 3-Year EPS without NRI Growth Rate too high?
Iovance Biotherapeutics' current 3-Year EPS without NRI Growth Rate is 24.40%. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 15.95. Iovance Biotherapeutics' value of 24.40% is 53% above this industry median. Based on the distribution chart, Iovance Biotherapeutics ranks #456 out of 1160 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Iovance Biotherapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' 3-Year EPS without NRI Growth Rate compare to ABCL and RCUS?
According to the Biotechnology industry distribution chart, Iovance Biotherapeutics ranks #456 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This puts Iovance Biotherapeutics in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 15.95. Iovance Biotherapeutics' value of 24.40% is 53% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 15.95, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Iovance Biotherapeutics's current 3-Year EPS without NRI Growth Rate of 24.40% is 53% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Iovance Biotherapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iovance Biotherapeutics's current 3-Year EPS without NRI Growth Rate is 24.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Iovance Biotherapeutics (IOVA) has a current 3-Year EPS without NRI Growth Rate of 24.40%. The current 3-Year EPS without NRI Growth Rate is 24.40% and 53% above the Biotechnology industry median of 15.95. Iovance Biotherapeutics' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Iovance Biotherapeutics (IOVA), the current 3-Year EPS without NRI Growth Rate is 24.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
34GF Score
Get the complete analysis for IOVA
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IOVA has been successfully added to your 
